We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness

By LabMedica International staff writers
Posted on 30 Jan 2024
Print article
Image: As blood flows through the GO chips, cancer cells stick to antibodies embedded in the chip (Photo courtesy of University of Michigan)
Image: As blood flows through the GO chips, cancer cells stick to antibodies embedded in the chip (Photo courtesy of University of Michigan)

Approximately only half of cancer patients see a positive response to treatments, with the remaining experiencing inadequate outcomes. The high costs and potential adverse reactions of treatments make it crucial for clinicians to quickly determine their effectiveness, or if an alternative therapy is more suitable. Presently, it can take weeks or months to fully gauge the success of cancer treatment, typically using CT scans to measure significant size changes in tumors. While tumor biopsies offer more precise data, their infrequency limits the ability to provide ongoing updates. As a solution, many clinicians are now resorting to liquid biopsies, which involve testing for cancer indicators in a patient's blood, like tumor-shed cancer cells. However, these tests require sufficiently high cell levels for detection. This is particularly challenging in lung cancer, where some FDA-approved methods for detecting blood-borne cancer cells are ineffective, often due to targeting a single, less common protein in lung cancers.

A breakthrough device now enables the determination of treatment efficacy within as early as four weeks by isolating minimal numbers of cancer cells from blood samples. Utilizing a chip to process these samples, doctors can track the quantity of cancer cells in a patient's blood to assess treatment effectiveness within the first month. This technology, known as the "GO chip," developed at the University of Michigan (Ann Arbor, MI, USA), excels where others have failed. It efficiently captures cancer cells using antibodies attached to graphene oxide sheets within the chip. These antibodies recognize a broad spectrum of cancer-specific proteins on cell surfaces. As blood flows through the chip's channels, the antibodies trap the cells, concentrating them for analysis. This not only allows for cell counting but also confirms their cancerous nature and tracks biochemical variations across patients and treatment phases.

The GO chip's capability to monitor lung cancer treatments was evaluated with 26 stage 3 lung cancer patients undergoing chemotherapy and immunotherapy. Samples were taken before treatment and after the first, fourth, 10th, 18th, and 30th weeks. The study discovered that a less than 75% reduction in blood cancer cell count by the fourth week indicated a higher likelihood of cancer persistence post-treatment. Additionally, it was observed that cancer cells from patients unresponsive to treatment exhibited activated genes potentially contributing to the cancer's resilience. These genes could be potential targets for future therapies, though more research is needed to explore this hypothesis.

“This technique has the potential to shift cancer diagnostics, moving from a delayed single assessment to a more continuous surveillance and facilitating the delivery of personalized cancer treatment,” said Shruti Jolly, professor of radiation oncology, associate chair of community practices at U-M and co-corresponding author of the study.

Related Links:
University of Michigan

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control

Print article

Channels

Molecular Diagnostics

view channel
Image: Prostate cancer cell image taken using a scanning electron microscope (Photo courtesy of LRI EM Unit)

New Discoveries of Prostate Cancer Evolution Pave Way for Genetic Test

Prostate cancer ranks as one of the most common cancers affecting men, and while it accounts for a significant number of male cancer fatalities, many men live with it rather than die from it.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Pathology

view channel
Image: The photoacoustic spectral response sensing instrument is based on low-cost laser diodes (Photo courtesy of Khan et al., doi 10.1117/1.JBO.29.1.017002)

Compact Photoacoustic Sensing Instrument Enhances Biomedical Tissue Diagnosis

The pursuit of precise and efficient diagnostic methods is a top priority in the constantly evolving field of biomedical sciences. A promising development in this area is the photoacoustic (PA) technique.... Read more

Industry

view channel
Image: The companies will develop genetic testing systems based on capillary electrophoresis sequencers (Photo courtesy of 123RF)

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.